Trials / Conditions / Psychotic Disorders

Psychotic Disorders

287 registered clinical trials studyying Psychotic Disorders — 34 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Sch NCT07455929	Charite University, Berlin, Germany	N/A
Recruiting	Racial Disparities in the Expression of Paranoia NCT07460453	Indiana University	N/A
Recruiting	CBT-CP for Veterans With SMI NCT06758414	VA Office of Research and Development	N/A
Not Yet Recruiting	Stratification and Treatment in Early Psychosis Study - ENHANCE NCT06778564	University of Oxford	Phase 3
Recruiting	Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Sp NCT07395206	Charite University, Berlin, Germany	N/A
Not Yet Recruiting	Effects of a Peer-facilitated, Acceptance-based Self-learning for Illness Management (PASIM) Program NCT07129369	Chinese University of Hong Kong	N/A
Recruiting	Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With NCT07360665	University of Trás-os-Montes and Alto Douro	N/A
Completed	Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia NCT07523256	Rinvil Renaldi	N/A
Active Not Recruiting	The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. NCT06993662	Rakitzi, Stavroula	Phase 1
Active Not Recruiting	TTM-Based Social Media Psychoeducation for Psychosis NCT07080827	Istanbul University - Cerrahpasa	N/A
Recruiting	Improving Heart and Metabolic Health in People With Severe Mental Illness Through a Long-term Clinical Trial NCT06781801	Vastra Gotaland Region	N/A
Recruiting	A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences NCT06929442	Massachusetts General Hospital	N/A
Not Yet Recruiting	Investigation of Objective Cognitive Effort in Neuropsychological Evaluation of Psychotic Disorders NCT06782672	University Hospital, Montpellier	—
Active Not Recruiting	Imagery Rescripting as a Treatment for Early Psychosis NCT06539780	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A
Recruiting	Magnetic Seizure Therapy for Psychotic Disorders NCT06581302	Shanghai Jiao Tong University School of Medicine	N/A
Recruiting	Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis NCT06410508	Nova Scotia Health Authority	N/A
Recruiting	Efficacy of an Online-Based Self-Help Intervention for Auditory Hallucinations in Persons With Psychotic Disor NCT06186570	Charite University, Berlin, Germany	N/A
Recruiting	Honest Open Proud for Psychotic and Bipolar Disorder in Norway NCT06384755	Oslo University Hospital	N/A
Recruiting	Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness NCT05962879	Massachusetts General Hospital	N/A
Completed	Impact of VVV Group for Veterans With SMI NCT05562674	VA Office of Research and Development	N/A
Recruiting	Sensory Profile and Early Clinical Signs of Calm Room Users NCT06839950	Centre Hospitalier Esquirol	—
Unknown	Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder NCT06086184	Vivantes Netzwerk für Gesundheit GmbH	N/A
Completed	iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders NCT05899348	University of California, San Diego	N/A
Recruiting	A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illne NCT05537376	VA Office of Research and Development	N/A
Recruiting	The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care NCT06005766	University of Jyvaskyla	N/A
Completed	Peer Approaches to Substances in Early Psychosis Programs: A Pilot Study of a Peer-Led Intervention NCT04517279	University of Texas at Austin	N/A
Recruiting	Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices NCT05982158	Swinburne University of Technology	N/A
Recruiting	RUFUS - Group Rumination-focused CBT for Negative Symptoms NCT05851950	Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital	N/A
Recruiting	Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis NCT05973110	The Royal Ottawa Mental Health Centre	N/A
Recruiting	Critical Time Intervention-Peer Support NCT05945277	Lisbon Institute of Global Mental Health - LIGMH	N/A
Recruiting	EEG Microstates Across At-Risk Mental States NCT06045897	Centre Hospitalier St Anne	N/A
Active Not Recruiting	Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders NCT05813080	Heinrich-Heine University, Duesseldorf	N/A
Completed	A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders NCT05633108	Eisai Co., Ltd.	—
Unknown	Side Effects of Psychiatric Medications - a Nested Case Control Cohort Historical Prospective Study NCT05872555	Mark Weiser, MD, Principal Investigator	—
Completed	Comparison of a Speech-Language Assessment Tool for Pragmatic and Discourse Skills in Schizophrenia Spectrum D NCT05742893	Centre Hospitalier Universitaire de Nice	N/A
Recruiting	Outcomes From Remediation and Behavioural Intervention Techniques NCT05731414	University of Toronto	N/A
Recruiting	Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Diso NCT05656469	Maastricht University Medical Center	N/A
Active Not Recruiting	Effects of a Peer-facilitated, Recovery-focused Self-illness Management Program for First-episode Psychosis NCT06487195	Chinese University of Hong Kong	N/A
Recruiting	RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic NCT05704582	Ciusss de L'Est de l'Île de Montréal	N/A
Active Not Recruiting	Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis NCT06192602	Chinese University of Hong Kong	N/A
Completed	EEG Outcomes From Cognitive Behavioural Therapy for Psychosis NCT05703698	University of Toronto	N/A
Completed	HCT Effect Among Patients With Psychotic Disorders NCT06077279	Alexandria University	N/A
Completed	Effect of Immersive Virtual Reality-based Cognitive Remediation in Patients With Mood - or Psychosis Spectrum NCT06038955	Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital	N/A
Recruiting	Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study NCT05500001	University of Alberta	N/A
Completed	Remote State Representation in Early Psychosis NCT05538832	University of Minnesota	EARLY_Phase 1
Completed	Weight Management Program for Patients With First Episode Psychosis NCT05207982	State University of New York at Buffalo	Phase 1
Unknown	Physical Activity, Psychopathology, and Quality of Life in People With Psychotic or Affective Disorders NCT05869409	University of Social Sciences and Humanities, Warsaw	—
Recruiting	Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls W NCT05445180	Douglas Mental Health University Institute	N/A
Completed	Depth of Anesthesia During Electroconvulsive Therapy NCT05308056	Region Örebro County	—
Terminated	Brain and Oculometric Markers of Emotional Facial Expression Recognition Deficits NCT05501405	Hôpital le Vinatier	N/A
Completed	Medication Reviews in Severe Mental Illness NCT05243160	Psychiatric Research Unit, Region Zealand, Denmark	N/A
Completed	Reducing Stigma Among Healthcare Providers (RESHAPE-cRCT) NCT04282915	George Washington University	N/A
Completed	Acceptance and Commitment Therapy (ACT) in Early Psychosis Patients NCT05210816	Saglik Bilimleri Universitesi	N/A
Completed	Psychotherapy for Psychosis, Adverse Events, and Substance Misuse NCT04546178	Nova Scotia Health Authority	N/A
Completed	Cultural Adaptation of Group CBT Psychosis Manual and Establishing Its Efficacy in Pakistan NCT07005388	Punjab Institute of Mental Health	N/A
Unknown	Illness Management and Recovery- a Cluster Randomized Controlled Trial Within a Forensic Mental Inpatient Sett NCT04695132	Karolinska Institutet	N/A
Completed	Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder NCT05321602	Luye Pharma Group Ltd.	Phase 1
Terminated	Cognitive Remediation and Supported Education in Psychotic Disorders NCT04040829	Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec	N/A
Completed	Game-based Telehealth Therapeutic Intervention in First Onset Psychosis NCT04799717	Stanford University	—
Recruiting	Dimensional and Developmental Profiles of Psychosis in Children and Adolescents NCT04370730	Assistance Publique - Hôpitaux de Paris	N/A
Unknown	Metacognitive Training as a Serious Game NCT04631939	Christina Andreou	N/A
Withdrawn	Psychodynamic Psychotherapy for Psychosis NCT04415541	Yale University	N/A
Completed	Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia". NCT04902066	Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital	N/A
Completed	Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders NCT04783285	CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas	N/A
Completed	Assessment and Treatment for Chronic Pain in Veterans With Serious Mental Illness NCT04118283	VA Office of Research and Development	N/A
Unknown	Ketogenic Diet for Psychotic Disorders NCT03873922	Kuopio University Hospital	N/A
Completed	Virtual Cognitive Behavioural Therapy for Psychosis NCT04752449	University of Toronto	N/A
Completed	Examining Strategy Monitoring and Remediation Training NCT04756388	University of Toronto	N/A
Recruiting	Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders NCT04730518	Charite University, Berlin, Germany	N/A
Unknown	Effectiveness of Trauma Therapy in Patients With PTSD and Comorbid Psychotic Disorder NCT04911010	University of Hamburg-Eppendorf	N/A
Active Not Recruiting	Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial NCT04338152	University of California, Los Angeles	N/A
Completed	Relative Bioavailability of LY03010 Compared to Listed Drug NCT04922593	Luye Pharma Group Ltd.	Phase 1
Completed	Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider Engagemen NCT04602741	Centre for Addiction and Mental Health	N/A
Completed	Effect of a Peer-led Self-management Program for Recent-onset Psychosis NCT04166019	Chinese University of Hong Kong	N/A
Completed	CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis NCT04180709	University of Cambridge	N/A
Completed	RELATE - Efficacy and Feasibility of a Cognitive Behavioural Module for Distressing Auditory Verbal Hallucinat NCT04578314	University of Hamburg-Eppendorf	N/A
Active Not Recruiting	Reconnecting to Ourselves and Others in Virtual Meetings (ROOM) NCT06360562	Massachusetts General Hospital	N/A
Unknown	Sleep Disturbances in Patients With Psychotic Symptoms (AkuSleep) NCT04290650	Oslo University Hospital	N/A
Completed	Facilitating Engagement in Evidence-Based Treatment for Early Psychosis NCT04532034	Temple University	N/A
Unknown	Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of CO NCT04445324	Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal	N/A
Unknown	VR-assisted CBT for Adolescents With Psychosis NCT04586868	Haukeland University Hospital	N/A
Completed	Pilot Study of Motivational Interviewing for Loved Ones NCT04010747	Boston Medical Center	N/A
Completed	The Role of Group Identity on the Community Integration of People With Severe Mental Disorder NCT04304417	Universidad Complutense de Madrid	—
Unknown	Cognitive Impairments in Psychotic Disorders NCT05597579	Sheba Medical Center	—
Recruiting	Cognitive Remediation in Forensic Mental Health Care NCT04610697	The Royal Ottawa Mental Health Centre	N/A
Completed	Fitforlife- Exercise in Care of Psychosis NCT04239612	Karolinska Institutet	N/A
Recruiting	Youth Experiences and Health Study NCT03332966	Finnish Institute for Health and Welfare	—
Completed	Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Youn NCT05686772	Laval University	—
Unknown	Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders NCT05726617	Ciusss de L'Est de l'Île de Montréal	N/A
Completed	Prevalence of Traumatic Events and PTSD in Immigrant and Non-immigrant Patients With Psychotic Disorder NCT04867447	Parc de Salut Mar	—
Unknown	ReMindCare App for Patients From First Episode of Psychosis Unit. NCT03807388	Instituto de Investigacion Sanitaria INCLIVA	N/A
Suspended	Convergent and Concurrent Validity Between Clinical Recovery and Personal-civic Recovery in Mental Health NCT04125030	Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal	—
Completed	Reproductive Life Planning for Women With Mental Illness NCT03969589	VA Office of Research and Development	N/A
Completed	Implementation of Family Involvement for Persons With Psychotic Disorders. NCT03869177	University of Oslo	N/A
Unknown	Computerized Cognitive Remediation Therapy in Adolescents With a First Psychotic Episode NCT05405946	Fundació Sant Joan de Déu	N/A
Completed	Treating Smokers With Mental Illness NCT03822416	University of Minnesota	Phase 2
Completed	Mobile After-Care Intervention to Support Post-Hospital Transition (MACS) NCT03769493	Butler Hospital	N/A
Completed	Psychosis Screening in Juvenile Justice NCT03583073	Brown University	N/A
Completed	Resiliency Training on the College Campus NCT06038786	Massachusetts General Hospital	N/A
Completed	Substance Misuse To Psychosis for Ketamine (SToP-K) NCT03485339	The University of Hong Kong	—
Completed	Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis NCT03316664	Psychiatric University Hospital, Zurich	N/A
Recruiting	Semantic and Syntactic Computerized Analysis of Free Speech NCT03525054	University Hospital, Brest	—
Unknown	A Novel Treatment Approach for Self-Stigma in First Episode Psychosis NCT03491852	Queen's University	N/A
Completed	Mindfulness Group-based Intervention for Early Psychosis NCT03143907	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Completed	Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis NCT03409393	Rigshospitalet, Denmark	N/A
Completed	Using Short Message Service as a Means of Clinical Engagement in Early Psychosis NCT04379349	Centre for Addiction and Mental Health	N/A
Terminated	This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psycho NCT03230097	Boehringer Ingelheim	Phase 2
Completed	VIA Family - Family Based Early Intervention Versus Treatment as Usual NCT03497663	Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital	N/A
Completed	Exercise and Overnight Motor Sequence Task NCT03800368	The University of Hong Kong	N/A
Unknown	Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT) NCT02873884	University Hospital, Caen	—
Completed	Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) NCT02782442	University of Minnesota	N/A
Unknown	Tocilizumab in Schizophrenia NCT02874573	Brian Miller	Phase 1
Completed	The Role of Nitric Oxide in Cognition in Schizophrenia NCT02906553	King's College London	N/A
Terminated	Brain Effects of Memory Training in Early Psychosis NCT02584114	University of Calgary	N/A
Completed	Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients NCT02897167	Fundación Marques de Valdecilla	—
Completed	Partners in Wellness: Evaluation of a Pay for Performance Program for High-Utilizers of Mental Health Services NCT06053346	Stanford University	N/A
Completed	A Comparison of Cognitive Training Approaches in Psychotic Disorders NCT03024203	Queen's University	N/A
Completed	Striatal Connectivity and Clinical Outcome in Psychosis NCT02822092	Northwell Health	—
Completed	Transcranial Brain Stimulation and Its Underlying Neural Mechanisms as a Novel Treatment for Auditory Hallucin NCT02769507	University of Bergen	N/A
Completed	Hormonal and Inflammatory Biomarkers and Response to Cognitive Remediation in Recent-onset Psychosis NCT04418570	Corporacion Parc Tauli	N/A
Completed	Implementation of National Guidelines for Treatment of Psychoses NCT03271242	University Hospital, Akershus	—
Completed	Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for Psychosis NCT02787135	Philipps University Marburg	N/A
Unknown	Siltuximab in Schizophrenia NCT02796859	Brian Miller	Phase 1 / Phase 2
Completed	The Staged Treatment in Early Psychosis Study NCT02751632	Orygen	Phase 3
Completed	The Role of Personal Identity in Psychotic Symptoms: a Study With the Repertory Grid Technique NCT03820362	University of Barcelona	—
Completed	Participatory Video as a Recovery-Oriented Intervention in Early Psychosis NCT02360566	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Terminated	Role Functioning Changes NOS NCT02505022	Northwestern University	—
Completed	Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness NCT02663349	Minneapolis Veterans Affairs Medical Center	N/A
Unknown	Is Health Coaching Effective for Improving Metabolic Health in People With Psychosis Disorders? NCT01752465	University of British Columbia	N/A
Completed	The Impact of a Helplessness and Recovery of an Empowerment Intervention on People Diagnosed With Schizophreni NCT02968667	Fakeeh College for Medical Sciences	Phase 2
Completed	Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders NCT02930005	The University of Texas Health Science Center, Houston	Phase 2
Completed	A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-A NCT02431702	Janssen Scientific Affairs, LLC	Phase 3
Completed	Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study NCT02342210	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Completed	Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse NCT03558529	Manchester Academic Health Science Centre	—
Completed	Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study NCT02739932	University of Calgary	—
Completed	Feasibility Trial of CBT for Depersonalisation in Psychosis NCT02427542	King's College London	Phase 1
Active Not Recruiting	Cannabinoids, Learning, and Memory NCT02407808	Yale University	Phase 1
Completed	A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis NCT02398292	Oregon Health and Science University	N/A
Withdrawn	Study of the Effect of Dosing on Clozapine Levels NCT02286206	University of British Columbia	Phase 4
Completed	Self-Management and Recovery Technology Psychosocial Intervention Trial NCT02474524	Swinburne University of Technology	N/A
Unknown	Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up NCT03883204	Fundación Marques de Valdecilla	Phase 4
Terminated	Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement NCT02841956	University of California, Davis	N/A
Withdrawn	Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications NCT02213887	University of British Columbia	Phase 4
Completed	Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis NCT01981356	VA Office of Research and Development	EARLY_Phase 1
Completed	Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis NCT02566057	Northwell Health	N/A
Unknown	Routine Outcome Monitoring in Mental Health Outpatient NCT02095457	Shalvata Mental Health Center	N/A
Completed	Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders NCT02097563	University of California, Los Angeles	Phase 2
Unknown	Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up NCT03090503	Fundación Marques de Valdecilla	Phase 4
Completed	Cognitive Behavioural Therapy- Social Functioning In Adolescence With Recent Onset Schizophrenia NCT03217955	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A
Unknown	Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up NCT02532491	Fundación Marques de Valdecilla	Phase 4
Completed	Short-term Working Memory and Executive Training NCT02168166	Queen's University	N/A
Completed	Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize... NCT02748486	University of Warsaw	N/A
Completed	A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Ho NCT02085447	University Hospitals Cleveland Medical Center	N/A
Unknown	Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations NCT01977521	Iris Sommer	N/A
Completed	Group Training for Social Skills in Psychosis NCT02181777	King's College London	N/A
Completed	Problem-solving-based Bibliotherapy Program for Family Caregivers NCT02391649	Chinese University of Hong Kong	N/A
Completed	Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Particip NCT02087579	Janssen Research & Development, LLC	Phase 1
Unknown	Serial Comparisons of Abdominal and Neurological MRI Scans NCT02009969	University of British Columbia	—
Completed	Motivational Intervention for Physical Activity in Psychosis NCT02648321	The University of Hong Kong	N/A
Unknown	Irish Omega-3 Study NCT02848469	University College Cork	Phase 2
Completed	The Family VOICE Study NCT01804582	University of Maryland, Baltimore	N/A
Completed	Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness NCT01779440	Dartmouth-Hitchcock Medical Center	N/A
Completed	Cannabinoids and Cerebellar-Motor Functioning NCT01853020	Yale University	EARLY_Phase 1
Completed	Lifestyle Intervention for Diabetes and Weight Management in Psychosis NCT01828931	Centre for Addiction and Mental Health	N/A
Completed	Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI NCT01739127	University of British Columbia	—
Completed	Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis NCT01688765	Mclean Hospital	—
Unknown	Antipsychotic to Treat Psychosis Syndrome NCT02137616	Central South University	N/A
Completed	Antipsychotics and Risk of Hyperglycemic Emergencies NCT02582736	Canadian Network for Observational Drug Effect Studies, CNODES	—
Completed	A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention NCT05012709	Jianan Psychiatric Center, Ministry of Health and Welfare	N/A
Completed	Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses NCT02807688	Azienda ULSS di Verona e Provincia	N/A
Completed	Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI) NCT00983476	VA Office of Research and Development	N/A
Completed	Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations NCT01512290	UMC Utrecht	N/A
Completed	Cognitive Therapy for Distressing Visual Hallucinations: A Pilot Study NCT02782507	Newcastle University	—
Terminated	The Topical Niacin Skin Flush Test in First Episode Psychosis NCT01324297	Nova Scotia Health Authority	—
Completed	Bergen Psychosis Project 2 - The Best Intro Study NCT01446328	Haukeland University Hospital	Phase 4
Completed	Improving Outcomes for Individuals With Serious Mental Illness and Diabetes NCT01410357	Case Western Reserve University	N/A
Completed	Supported Employment: Motivational Enhancement for Entry and Outcome NCT01041976	VA Office of Research and Development	Phase 2
Completed	Monitoring and Management for Metabolic Side Effects of Antipsychotics NCT01875861	VA Office of Research and Development	N/A
Unknown	Mental Health Related to School Dropout in Luxembourg NCT01354236	Public Research Centre Health, Luxembourg	—
Completed	Adult Study Oxytocin - Behavioral NCT02567032	University of California, San Francisco	EARLY_Phase 1
Unknown	Epidemiology Study of Psychosis NCT01423669	The University of Hong Kong	—
Completed	Acute Glycine Pharmacodynamic Study NCT01610011	Mclean Hospital	N/A
Unknown	Optimal Duration of Early Intervention for Psychosis NCT01202357	The University of Hong Kong	N/A
Completed	A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs) NCT00677898	US Department of Veterans Affairs	N/A
Completed	Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention NCT00980252	University of Illinois at Chicago	N/A
Completed	Extended Specialized Assertive Intervention for First Episode Psychosis NCT00914238	University of Copenhagen	N/A
Completed	Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) NCT00790517	Kaiser Permanente	Phase 2
Completed	Stage-specific Case Management for Early Psychosis NCT00919620	The University of Hong Kong	N/A
Completed	D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia NCT00960219	China Medical University Hospital	Phase 2
Completed	Effects of Delta-9-THC and Iomazenil in Healthy Humans NCT00982982	Yale University	EARLY_Phase 1
Completed	A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophreni NCT01094249	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1
Completed	Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics NCT00806234	Johns Hopkins University	Phase 4
Completed	Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in NCT00821600	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1
Completed	Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year NCT02526030	Fundación Marques de Valdecilla	Phase 4
Enrolling By Invitation	Psychiatric Genotype/Phenotype Project Repository NCT00762866	Vanderbilt University	—
Completed	Forensic Assertive Community Treatment: An Emerging Model of Service Delivery NCT01313052	University of Rochester	Phase 3
Completed	Cannabinoids, Neural Synchrony, and Information Processing NCT00708994	Yale University	EARLY_Phase 1
Completed	Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study NCT01924715	Nova Scotia Health Authority	—
Completed	Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia NCT00936351	US Department of Veterans Affairs	N/A
Unknown	Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder NCT00541502	Genovate Biotechnology Co., Ltd.,	—
Completed	Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease NCT00535145	Ortho-McNeil Janssen Scientific Affairs, LLC	Phase 4
Completed	Early Detection and Intervention for the Prevention of Psychosis NCT00531518	MaineHealth	N/A
Completed	Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis NCT00484302	Bispebjerg Hospital	N/A
Completed	Effect of Antipsychotics on Appetite Regulation NCT00903916	University of North Carolina, Chapel Hill	—
Terminated	Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders NCT00508560	US Department of Veterans Affairs	N/A
Terminated	Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder NCT00457899	AstraZeneca	Phase 3
Terminated	Anticholinergic Burden in Schizophrenia NCT00715377	Centre for Addiction and Mental Health	N/A
Completed	Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. NCT00488319	Janssen Research & Development, LLC	Phase 3
Unknown	Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Ps NCT00465920	University of Cologne	Phase 2
Terminated	FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis NCT00486798	AstraZeneca	Phase 3
Completed	A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment NCT00420823	Melbourne Health	Phase 2 / Phase 3
Completed	Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects NCT00567034	Mclean Hospital	Phase 1
Terminated	Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment NCT00282165	UMC Utrecht	Phase 4
Withdrawn	Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia NCT00276263	Herzog Hospital	Phase 2
Completed	First Episode Schizophrenia and Cannabis-Related Disorder Study NCT00573287	Dartmouth-Hitchcock Medical Center	N/A
Completed	Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II NCT00377117	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	—
Completed	Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis NCT00307216	University of North Carolina, Chapel Hill	N/A
Completed	Side Effects of Antipsychotic Medications NCT00363181	Stanford University	—
Completed	A Clinical Trial on the Antipsychotic Properties of Cannabidiol NCT00309413	University of Cologne	Phase 2
Completed	Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis NCT00369239	Janssen Pharmaceutica N.V., Belgium	Phase 4
Terminated	Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medi NCT00287027	National Alliance on Mental Illness New Hampshire	—
Completed	Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With NCT00299702	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 4
Completed	Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatmen NCT00783185	University of Konstanz	Phase 1
Completed	Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective P NCT02305823	Fundación Marques de Valdecilla	Phase 4
Completed	Culturally Responsive Person-Centered Care for Psychosis NCT00231933	Yale University	Phase 1
Completed	Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up NCT02534363	Fundación Marques de Valdecilla	Phase 4
Completed	Rapid Tranquillization Trial: TREC-India II NCT00455234	Christian Medical College, Vellore, India	Phase 3
Completed	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder NCT00130923	Dartmouth-Hitchcock Medical Center	Phase 4
Completed	Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) NCT00844922	Merck Sharp & Dohme LLC	Phase 2
Completed	An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression NCT00128505	Corcept Therapeutics	Phase 3
Completed	Clinical and Biological Characteristics of Psychotic Depression NCT00576095	Stanford University	—
Completed	Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine NCT00224302	Central Institute of Mental Health, Mannheim	Phase 4
Completed	Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease NCT00125138	Lundbeck LLC	Phase 2
Completed	A Brief Community Linkage Intervention for Dually Diagnosed Individuals NCT00137267	US Department of Veterans Affairs	N/A
Completed	A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents NCT00163865	Bayside Health	—
Completed	A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CON NCT00216632	Janssen Pharmaceutica N.V., Belgium	Phase 4
Completed	Functional Rehabilitation of Older Patients With Schizophrenia NCT00237796	US Department of Veterans Affairs	N/A
Completed	The Immune System and Psychiatric Disorders NCT00184418	Norwegian University of Science and Technology	—
Completed	Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia NCT00491569	China Medical University Hospital	Phase 2
Completed	Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia NCT00328276	China Medical University Hospital	Phase 2
Completed	Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risp NCT00174200	Pfizer	N/A
Completed	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Diso NCT00137020	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4
Completed	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia NCT00158223	Icahn School of Medicine at Mount Sinai	Phase 4
Completed	Fast Titration Of Quetiapine Versus Currently Approved Titration NCT00254813	AstraZeneca	Phase 3
Unknown	Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Ot NCT00563017	Hospital Authority, Hong Kong	N/A
Completed	A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosi NCT00246259	Janssen-Ortho Inc., Canada	Phase 4
Completed	A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Table NCT00216476	Janssen-Cilag International NV	Phase 3
Completed	Safety Study of ORG 34517 for Major Depression With Psychotic Features NCT00226278	Weill Medical College of Cornell University	Phase 2
Completed	Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population NCT00253240	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	—
Completed	A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression NCT00130676	Corcept Therapeutics	Phase 3
Completed	A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depre NCT00128479	Corcept Therapeutics	Phase 3
Completed	Antipsychotic Discontinuation in Alzheimer's Disease NCT00417482	New York State Psychiatric Institute	Phase 4
Completed	A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Ps NCT00212797	Merck Sharp & Dohme LLC	Phase 2
Completed	Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms NCT00169988	Northwell Health	N/A
Completed	Psychiatric Advance Directives for Improved Mental Health Care NCT00105794	US Department of Veterans Affairs	N/A
Completed	Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients NCT00255918	University of Colorado, Denver	Phase 1
Completed	The Effects of Risperidone and Olanzapine on Thinking NCT00108368	US Department of Veterans Affairs	Phase 4
Completed	Genetics of Symptomatology and Treatment Response in Psychotic Major Depression NCT00691535	Stanford University	—
Completed	A Registry of Treatment Adherence for Patients With Schizophrenia NCT00283517	Janssen-Cilag, S.A.	—
Completed	Enhancing the Prospective Prediction of Psychosis NCT00291200	Yale University	—
Unknown	Dutch Prediction of Psychosis Study NCT00188981	UMC Utrecht	—
Completed	Psychosis: Early Detection, Intervention and Prevention NCT01597141	MaineHealth	N/A
Completed	Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset P NCT00145444	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting NCT00932529	University of Bergen	Phase 4
Unknown	Medication Adherence in Older People With Psychosis NCT00071604	Veterans Medical Research Foundation	N/A
Completed	A Comparative Study of New Medications for Psychosis in Adolescents NCT00222495	University of Minnesota	N/A
Completed	RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain I NCT00458367	Janssen Pharmaceutica N.V., Belgium	—
Completed	Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophreni NCT00236353	Janssen, LP	Phase 3
Completed	Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental Illness NCT00621465	New York State Psychiatric Institute	N/A
Completed	CAFE Comparison of Atypicals in First Episode of Psychosis NCT00034892	AstraZeneca	Phase 3
Completed	Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients NCT00159770	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Indicated Prevention of Psychotic Disorders With Low-dose Lithium NCT00202306	Melbourne Health	Phase 4
Completed	Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants NCT00419146	University Hospital, Aker	Phase 2 / Phase 3
Completed	A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long NCT00034775	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3
Completed	A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of NCT00249171	Janssen Pharmaceutica N.V., Belgium	Phase 4
Completed	A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia NCT00246285	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3
Completed	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patient NCT00044187	Eli Lilly and Company	Phase 4
Completed	A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment o NCT00236457	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3
Completed	Recovery Therapy Trial NCT00239122	Melbourne Health	N/A
Terminated	Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents NCT00183612	Massachusetts General Hospital	N/A
Completed	A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the NCT00249223	Janssen Pharmaceutica N.V., Belgium	Phase 3
Completed	A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment NCT00253136	Janssen, LP	Phase 3
Completed	Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke NCT00307203	National Institute on Drug Abuse (NIDA)	Phase 4
Terminated	Treatment of Schizoaffective Disorder Using Mifepristone NCT00725270	Stanford University	Phase 2 / Phase 3
Unknown	Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis NCT00157313	Bispebjerg Hospital	N/A
Completed	Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period NCT00236548	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3
Completed	A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With NCT00249132	Janssen, LP	Phase 3